Business Daily.
.
The Times Real Estate
A+ R A-

Research and Markets: CF101 (Dry Eye Syndrome) - Forecast and Market Analysis to 2022

E-mail Print PDF
image image

DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/mfk4fv/cf101_dry_eye) has announced the addition of the "CF101 (Dry Eye Syndrome) - Forecast and Market Analysis to 2022" report to their offering.

Dry eye syndrome (DES), or keratoconjunctivitis sicca, is a multifactorial disease of the eye caused by dryness, decreased tear production, or increased tear film evaporation. DES, which is often referred to simply as dry eye, is the most prevalent form of ocular discomfort and irritation.

The most common symptoms of DES are ocular irritation and discomfort, foreign body sensation, fatigue, and visual disturbances, which interfere with daily activities. In the elderly population, it is the most common reason for seeking eye care, and this is expected to increase exponentially with an aging demographic.

CF-101 is Can-Fite BioPharma's lead drug compound, which is exclusively licensed to OphthaliX for development in ophthalmic indications, including DES, glaucoma, and uveitis. It is a novel A3AR agonist, generically known as IB-MECA (methyl 1-[N6-(3-iodobenzyl)-adenin-9-yl]-b-D-ribofuronamide).

A3AR is highly expressed in inflammatory cells and is thought to suppress cellular signal transduction, which contributes to inflammation and the production of inflammatory cytokines. CF-101 shows therapeutic intervention by causing downregulation of the PI3K/PKB/Akt pathway, ultimately resulting in the inhibition of tumor necrosis factor-a (TNF-a) and macrophage inflammatory protein-1a (MIP-1a).

Scope

- Overview of DES, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.

- Detailed information on CF-101 including product description, safety and efficacy profiles as well as a SWOT analysis.

- Sales forecast for CF-101 for the top two countries from 2012 to 2022.

- Sales information covered for Japan and China.

For more information visit http://www.researchandmarkets.com/research/mfk4fv/cf101_dry_eye

About Research and Markets

Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Business Daily Media